Pleconaril Sanofi Synthélabo/ViroPharma.
Pleconaril is an oral antiviral agent being developed by ViroPharma and Sanofi-Synthélabo (formerly Sterling Winthrop) for the potential treatment of several picornavirus-induced infections, including respiratory diseases and viral meningitis. A number of phase III clinical trials have been completed, and several others are ongoing [319499], [343187], [346302], [359231]. In early 1999, an NDA filing for viral meningitis was expected by the end of 1999 [313588], [319499]. However, an NDA had not been filed by February 2000 and, at this time, filing in the US was expected in 2000 for viral meningitis and 2001 for viral respiratory syndrome, while in Europe filing was expected in 2001 and 2002 for these indications, respectively [359231]. In July 2000, Salomon Smith Barney predicted a launch date of 2002 [387350]. In October 1999, Lehman Brothers predicted a 70% chance of the product reaching the market, with a possible launch date anticipated for 2001 and potential peak sales of US$50 million in 2009 [346267].
Novartis Research Institute, General Dermatology, PO Box 80, Brunner Strasse 59, A-1235, Vienna, Austria. andreas.billich@pharma.novartis.com
A
A
Billich
D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D002986:Clinical Trials as Topic; D000075202:Contraindications; D015507:Drugs, Investigational / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D010069:Oxadiazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D010080:Oxazoles; D010849:Picornaviridae / Q000187:drug effects*; D010850:Picornaviridae Infections / Q000188:drug therapy / Q000821:virology; D013329:Structure-Activity Relationship
D000998:Antiviral Agents; D015507:Drugs, Investigational; D010069:Oxadiazoles; D010080:Oxazoles; C115201:pleconaril